Aqualung Therapeutics

Aqualung Therapeutics, founded in Tucson, AZ and Jupiter, FL, is an early-stage biotech company focused on developing therapeutic antibodies to combat acute and chronic lung diseases. Their core mission is to provide an immune-focused biologic platform addressing serious inflammatory and fibrotic disorders. The company has identified eNAMPT (extracellular nicotinamide phosphoribosyltransferase) as a key DAMP and upstream activator of inflammation, and their leading product, ALT-100, targets this pathway to reduce lung inflammation.

Notable figures associated with Aqualung Therapeutics include its founders and key scientific advisors who have extensive backgrounds in immunology and pulmonary medicine. The company has secured significant investment from biotech-focused venture capital firms. Aqualung's key achievements include the initiation of the PUERTA Phase 2A ARDS clinical trial, marking a significant milestone in the development of their lead therapeutic antibody. The overall impact of Aqualung Therapeutics lies in its potential to provide groundbreaking treatments for patients suffering from severe lung conditions, thereby addressing a critical unmet medical need.